Canntab Therapeutics Limited

Canntab Therapeutics — Investor Presentation (September 2022)

14 slides from Canntab Therapeutics's investor presentation, September 2022

  1. Slide 1: Corporate Presentation

    CORPORATE PRESENTATION OUR ONLINE STORE IS OPEN! CSE: PILL | OTCQB: CTABF | FSE:TBF1 CSE: PILL | OTCQB: CTABF | FSE:TBF1 September 2022 Canntab Therapeutics Limited © 2022

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "b

  3. Slide 3: What We Do

    WHAT WE DO We are the leading innovator of cannabinoid and terpene blends in hard pill form for therapeutic applications.  OUR ONLINE STORE IS OPEN!  Three patents granted in the United States, Canada, and Australia.  We are now on the Ontario Cannabis Store (OCS), and the Nova Scotia Cannabis St

  4. Slide 4: Strong IP Portfolio

    STRONG IP PORTFOLIO 3 patents granted, with 7 more patents pending in the United States and Canada covering our proprietary processes and hard pill formulations for,  Extended Release In August 2019, the Geneva-based International  Sustained Release Preliminary Report on Patentability (“IPRP”) ind

  5. Slide 5: Proprietary Process

    PROPRIETARY PROCESS Our patent pending proprietary processes allows us to create hard pill formulations that starts with the highest quality cannabis oil in water emulsions, a unique process in the industry to date. Oil emulsion >> wet granulation >> dried granulation >> blending >> tablet pressing

  6. Slide 6: Meeting Medical Standards

    MEETING MEDICAL STANDARDS Current delivery mechanisms such as smoking or vaping cannabis, consuming edibles, gel caps, oils and tincture (droppers) do not provide the medical community, including Doctors, patients or the average consumer, with an attractive and professional cannabis solution. CANNTA

  7. Slide 7: Therapeutic Window

    THERAPEUTIC WINDOW Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop. Edibles dosing is unpredictable, making it difficult to maintain therapeutic relief. Our solution, an extended release (XR) tablets with flash melt technology, quickly brings the patien

  8. Slide 8: How We Generate Revenue

    HOW WE GENERATE REVENUE As of March 15th 2021, we’ve manufactured almost two million hard pills at our Markham Ontario facility. These hard pills are for our partners, including MediPharm (Toronto) and Cann Global (Australia), and for our online store, the Ontario Cannabis Store (OCS), and the Nova

  9. Slide 9: Tablet Economics

    TABLET ECONOMICS Note: Sensitivity Analysis is meant to be illustrative and is not intended to used as a forecast. Canntab Therapeutics Limited © 2022 CSE: PILL | OTCQB: CTABF | FSE:TBF1 9

  10. Slide 10: Capitalization

    CAPITALIZATION Canntab Therapeutics Limited © 2022 CSE: PILL | OTCQB: CTABF | FSE:TBF1 10

  11. Slide 11: Management Team

    MANAGEMENT TEAM Richard Goldstein, Co-Founder Laxaminarayan Joshi Chief Financial Officer, Interim CEO Chief Science Officer  Founder First Republic Capital, Co-Founder Fraser  Over 20 years of experience in pharmaceuticals. McKenzie, former EVP/Head of IB at Standard Securities.  Previously was

  12. Slide 12: Summary

    SUMMARY  Our new online store is open, and includes a telehealth department that facilitates registration and customer care throughout the purchase process.  Our Instacann products launched on the OCS website on January 25th, 2022, and on the Nova Scotia (NSLC) on August 22nd.  We received a US P

  13. Slide 13: Looking at the Future

    LOOKING AT THE FUTURE  Blood level studies in Canada and Australia will be conducted in 2022, as the first steps towards further clinical trials designed to advance our understanding of Canntab’s unique formulations.  Partnering with an MSO in the United States, or internationally, to further our

  14. Slide 14: Contact Us

    CONTACT US Richard Goldstein Co-founder & Chief Financial Officer, Interim Chief Executive Officer (647) 209-3279 Richard@Canntab.ca Frank Candido Business Development Consultant (514) 969-5530 Frank@Canntab.ca Canntab Therapeutics Limited © 2022 CSE: PILL | OTCQB: CTABF | FSE:TBF1 14

Canntab Therapeutics — Investor Presentation (September 2022) on 6ix